The following articles (labelled with PubMed ID or TBD) are for your review
PMID | Data | Article Title | Organization |
26762835 |
342 |
Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2). |
Icahn School of Medicine At Mount Sinai |
25000588 |
72 |
Discovery of selective and orally bioavailable protein kinase C¿ (PKC¿) inhibitors from a fragment hit. |
Abbvie Bioresearch Center |
23394126 |
170 |
Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR). |
Exelixis |
23398373 |
88 |
Design and optimization of selective protein kinase C¿ (PKC¿) inhibitors for the treatment of autoimmune diseases. |
Vertex Pharmaceuticals |
23039927 |
44 |
Multitargeted drug development: Discovery and profiling of dihydroxy substituted 1-aza-9-oxafluorenes as lead compounds targeting Alzheimer disease relevant kinases. |
Martin-Luther-University Halle-Wittenberg |
22625994 |
28 |
Structure-activity studies on the spiroketal moiety of a simplified analogue of debromoaplysiatoxin with antiproliferative activity. |
Kyoto University |
9677190 |
49 |
Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. |
University of California |
18077363 |
314 |
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
University of Oxford |
17977729 |
40 |
Design and physicochemical properties of new fluorescent ligands of protein kinase C isozymes focused on CH/pi interaction. |
Kyoto University |
17935989 |
146 |
Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and preliminary pharmacokinetics. |
Abbott Laboratories |
16876403 |
85 |
Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure. |
Banyu Tsukuba Research Institute In Collaboration With Merck Research Laboratories |
12954055 |
47 |
Synthesis and discovery of macrocyclic polyoxygenated bis-7-azaindolylmaleimides as a novel series of potent and highly selective glycogen synthase kinase-3beta inhibitors. |
Johnson and Johnson Pharmaceutical Research and Development |
8289196 |
7 |
New hexahydroxybiphenyl derivatives as inhibitors of protein kinase C. |
University of North Carolina |
10999477 |
40 |
Synthesis and PKC isozyme surrogate binding of indothiolactam-V, a new thioamide analogue of tumor promoting indolactam-V. |
Kyoto University |
| 80 |
Synthesis and PKC inhibitory activities of balanol analogs with a cyclopentane substructure |
TBA |
22014550 |
337 |
Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD). |
Ansaris |
21696964 |
12 |
Generation of 'Unnatural Natural Product' library and identification of a small molecule inhibitor of XIAP. |
Keio University |
21548579 |
4 |
Hippolides A-H, acyclic manoalide derivatives from the marine sponge Hippospongia lachne. |
Second Military Medical University |
21035334 |
55 |
Discovery and selectivity-profiling of 4-benzylamino 1-aza-9-oxafluorene derivatives as lead structures for IGF-1R inhibitors. |
Martin-Luther-University Halle-Wittenberg |
20817520 |
40 |
Role of the phenolic hydroxyl group in the biological activities of simplified analogue of aplysiatoxin with antiproliferative activity. |
Kyoto University |
20346655 |
117 |
Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinases. |
Abbott Laboratories |
19926477 |
100 |
2,4-Diaminopyrimidine MK2 inhibitors. Part II: Structure-based inhibitor optimization. |
Abbott Laboratories |
8176401 |
21 |
Anti-AIDS Agents, 11. Betulinic Acid and Platanic Acid as Anti-HIV Principles from Syzigium claviflorum, and the Anti-HIV Activity of Structurally Related Triterpenoids |
TBA |
| 77 |
Synthesis and protein kinase C inhibitory activities of indane analogs of balanol |
TBA |
| 70 |
Potent and selective PKC inhibitory 5-membered ring analogs of balanol with replacement of the carboxamide moiety |
TBA |
| 40 |
Heteroatom effect in the PKC inhibitory activities of perhydroazepine analogs of balanol |
TBA |
| 88 |
Novel PKC inhibitory analogs of balanol with replacement of the ester functionality |
TBA |
19379015 |
40 |
Conformationally constrained analogues of diacylglycerol (DAG). 31. Modulation of the biological properties of diacylgycerol lactones (DAG-lactones) containing rigid-rod acyl groups separated from the core lactone by spacer units of different lengths. |
National Cancer Institute-Frederick |
19109017 |
4 |
(-)-Cercosporamide derivatives as novel antihyperglycemic agents. |
Daiichi Sankyo |
17875639 |
12 |
Protein kinase C epsilon regulates gamma-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of gamma2 subunits. |
University of California San Francisco |
18072722 |
42 |
Synthesis, conformational analysis, and biological evaluation of 1-hexylindolactam-V10 as a selective activator for novel protein kinase C isozymes. |
Kyoto University |
17658776 |
109 |
Design, synthesis, and biological activity of 5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one-based potent and selective Chk-1 inhibitors. |
Abbott Laboratories |
17287122 |
79 |
Discovery of 1,4-dihydroindeno[1,2-c]pyrazoles as a novel class of potent and selective checkpoint kinase 1 inhibitors. |
Abbott Laboratories |
16640328 |
13 |
Design and synthesis of 8-octyl-benzolactam-V9, a selective activator for protein kinase C epsilon and eta. |
Kyoto University |
15771419 |
134 |
Novel indolylindazolylmaleimides as inhibitors of protein kinase C-beta: synthesis, biological activity, and cardiovascular safety. |
Johnson & Johnson Pharmaceutical Research & Development |
15149684 |
59 |
3-(7-Azaindolyl)-4-arylmaleimides as potent, selective inhibitors of glycogen synthase kinase-3. |
Johnson & Johnson Pharmaceutical Research & Development |
14552791 |
35 |
Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitors. |
Eli Lilly |
12954072 |
46 |
New bivalent PKC ligands linked by a carbon spacer: enhancement in binding affinity. |
Georgetown University Medical Center |
12941331 |
96 |
Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3. |
Johnson & Johnson Pharmaceutical Research & Development |
12941324 |
66 |
Synthesis and binding selectivity of 7- and 15-decylbenzolactone-V8 for the C1 domains of protein kinase C isozymes. |
Kyoto University |
12749884 |
126 |
Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta. |
Eli Lilly |
11327599 |
25 |
Rational design, synthesis, and biological evaluation of rigid pyrrolidone analogues as potential inhibitors of prostate cancer cell growth. |
Georgetotwn University |
11266178 |
39 |
The amide hydrogen of (-)-indolactam-V and benzolactam-V8's plays a critical role in protein kinase C binding and tumor-promoting activities. |
Kyoto University |
11266177 |
26 |
The C4 hydroxyl group of phorbol esters is not necessary for protein kinase C binding. |
Kyoto University |
31757666 |
314 |
Discovery and optimization of heteroaryl piperazines as potent and selective PI3K? inhibitors. |
Merck |
30755337 |
95 |
Optimization of an azetidine series as inhibitors of colony stimulating factor-1 receptor (CSF-1R) Type II to lead to the clinical candidate JTE-952. |
Japan Tobacco |
10397502 |
36 |
Selective binding of bryostatin analogues to the cysteine rich domains of protein kinase C isozymes. |
Stanford University |
31693351 |
473 |
Discovery of 4 |
TBA |
30384048 |
365 |
ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells. |
University of Florida |
9135029 |
29 |
Modeling, chemistry, and biology of the benzolactam analogues of indolactam V (ILV). 2. Identification of the binding site of the benzolactams in the CRD2 activator-binding domain of PKCdelta and discovery of an ILV analogue of improved isozyme selectivity. |
Georgetown University Medical Center |
31526603 |
379 |
Structure-based rational design of staurosporine-based fluorescent probe with broad-ranging kinase affinity for kinase panel application. |
Takeda Pharmaceutical |
9003521 |
249 |
Synthesis and protein kinase C inhibitory activities of balanol analogs with replacement of the perhydroazepine moiety. |
Eli Lilly |
8709095 |
87 |
(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta. |
Eli Lilly |
26509640 |
234 |
Discovery of A-971432, An Orally Bioavailable Selective Sphingosine-1-Phosphate Receptor 5 (S1P5) Agonist for the Potential Treatment of Neurodegenerative Disorders. |
Abbvie Bioresearch Center |
23803585 |
7 |
Effects of the methoxy group in the side chain of debromoaplysiatoxin on its tumor-promoting and anti-proliferative activities. |
Kyoto University |
17618015 |
13 |
Bioactive peroxides as potential therapeutic agents. |
The Hebrew University of Jerusalem |
30274941 |
36 |
A novel 2,4-diaminopyrimidine derivative as selective inhibitor of protein kinase C theta prevents allograft rejection in a rat heart transplant model. |
Astellas Pharma |
30082069 |
359 |
ROCK inhibitors 3: Design, synthesis and structure-activity relationships of 7-azaindole-based Rho kinase (ROCK) inhibitors. |
Vertex Pharmaceuticals |
30026041 |
139 |
Synthesis and anticancer activity of novel bisindolylhydroxymaleimide derivatives with potent GSK-3 kinase inhibition. |
University College Cork |
29945794 |
193 |
ROCK inhibitors 2. Improving potency, selectivity and solubility through the application of rationally designed solubilizing groups. |
Vertex Pharmaceuticals |
28259529 |
31 |
Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer. |
The Ohio State University |
11451670 |
11 |
Hexosaminidase inhibitors as new drug candidates for the therapy of osteoarthritis. |
The Scripps Research Institute |
15689148 |
19 |
Bis-huperzine B: highly potent and selective acetylcholinesterase inhibitors. |
Shanghai Institute of Materia Medica |
15664516 |
21 |
Specificity and affinity of natural product cyclopentapeptide inhibitors against A. fumigatus, human, and bacterial chitinases. |
University of Dundee |
15026054 |
55 |
Meridianins, a new family of protein kinase inhibitors isolated from the ascidian Aplidium meridianum. |
Cnrs |